1. Market Research
  2. > Pathology
82 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Brain Cancer: Epidemiology Forecast to 2027

  • $ 3995
  • October 2018
  • 32 pages

Brain Cancer: Epidemiology Forecast to 2027 Summary Epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 119,717 cases in 2017 to 151,067 cases in 2027, at an ...

  • Brain Cancer
  • Cancer
  • Lymphoma
  • Pathology
  • Forecast

Brain Cancer Treatment Drugs Industry Forecasts - China Focus

  • $ 1800
  • June 2020
  • 102 pages

Rather than controlling edema, steroids destroy lymphoma tumor cells, but they are not a long-time cure for this tumor.

  • Anti-Infective
  • Brain Cancer
  • Lymphoma
  • China
  • Demand

Brain Cancer Treatment Drugs Markets in China

  • $ 4000
  • June 2020
  • 234 pages

RATHER THAN CONTROLLING EDEMA, STEROIDS DESTROY LYMPHOMA TUMOR CELLS, BUT THEY ARE NOT A LONG-TIME CURE FOR THIS TUMOR.

  • Brain Cancer
  • Lymphoma
  • Pharmaceutical
  • China
  • Bayer Schering Pharmaceutical Co., Ltd

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • October 2018
  • 124 pages

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027 Summary The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight majo ...

  • Brain Cancer
  • Lymphoma
  • Therapy
  • China
  • United States

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2019

  • $ 3500
  • March 2019
  • 90 pages

The vaccine candidate is in Phase II stage of development for glioblastoma (as a second line therapy) and diffuse large Bcell lymphoma (second and third line).

  • Brain Cancer
  • Immunotherapy
  • Lymphoma
  • Therapy
  • United States

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 156 pages

SIRPαFc was also highly efficacious in xenograft models of Burkitt lymphoma (Namalwa) and diffuse large B cell lymphoma (Toledo).

  • Brain Cancer
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2018

  • $ 3500
  • July 2018
  • 82 pages

Indications covered at the meeting will include Chronic Lymphocytic Leukemia, Multiple Myeloma, aggressive and indolent Lymphomas and Acute Leukemias.

  • Brain Cancer
  • Immunotherapy
  • Lymphoma
  • Therapy
  • Immunovaccine Inc.

Endoplasmin - Pipeline Review, H1 2020

  • $ 3500
  • February 2020
  • 52 pages

In March 2000, the company had initiated a Phase II trial of autologous human tumor-derived HSPPC-## (vitespen) for the treatment of indolent lymphoma.

  • Brain Cancer
  • Hospital
  • Lymphoma
  • Vaccine
  • Agenus Inc.

Endoplasmin - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 54 pages

In March 2000, the company had initiated a Phase II trial of autologous human tumor-derived HSPPC-## (vitespen) for the treatment of indolent lymphoma.

  • Brain Cancer
  • Hospital
  • Lymphoma
  • Vaccine
  • Agenus Inc.

Pontine Glioma - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 469 pages

IT IS IN PHASE II STAGE FOR FOLLICULAR LYMPHOMA.

  • Brain Cancer
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019
  • 88 pages

This call will provide an update on its ongoing phase ## clinical trials with Merck' s Keytruda in diffuse large B-cell lymphoma (DLBCL).

  • Brain Cancer
  • Hospital
  • Lymphoma
  • Therapy
  • United States

Anaplastic Astrocytoma - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 235 pages

THE DRUG CANDIDATE IS IN PHASE I/ II STAGE OF DEVELOPMENT FOR THE TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA, LYMPHOBLASTIC LYMPHOMA, SPLENIC, NODAL AND EXTRA NODAL MARGINAL ZONE LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA AS FIRST LINE THERAP

  • Brain Cancer
  • Hospital
  • Lymphoma
  • Targeted Therapy
  • Therapy

Protein Phosphatase 2A - Pipeline Review, H1 2020

  • $ 3500
  • February 2020
  • 51 pages

Protein Phosphatase 2A - Pipeline Review, H1 2020 Summary Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed ...

  • Brain Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • Lixte Biotechnology Holdings, Inc.

Oligodendroglioma - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 167 pages

It is in Phase I/ II stage of development for metastatic breast cancer and for Mantle cell lymphoma, natural killer lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoblastic lymphoma.

  • Brain Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

Brain Cancer Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020
  • 421 pages

Lymphomas Oxaliplatin and Irinotecan in Treating Young Patients with Refractory Solid Tumors or Lymphomas GDCT## NCT##, CDR##; U##CA##; ADVL##; NCI-2012-##; COG-ADVL## Oncology Astrocytoma, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, Chi

  • Brain Cancer
  • Clinical Trial
  • Hospital
  • Lymphoma
  • Oncology

Medulloblastoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 346 pages

It is in Phase II stage for follicular lymphoma.

  • Brain Cancer
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 66 pages

Its products are used for the treatment of various tumors such as multiple myeloma, lymphoma, leukemia, neuroblastoma, retinoblastoma and lung cancer.

  • Brain Cancer
  • Lymphoma
  • Therapy
  • United States
  • Noxxon Pharma AG

Anaplastic Astrocytoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 238 pages

The company registered Phase I/ II trial for the treatment of small lymphocytic lymphoma, lymphoblastic lymphoma, splenic, nodal and extra nodal marginal zone lymphoma, mantle cell lymphoma and follicular lymphoma.

  • Brain Cancer
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

Medulloblastoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020
  • 175 pages

Lymphomas Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma GDCT## NCT##, CDR##; NCI-2011-01980; U##CA##; ADVL##; COG-ADVL## Oncology Anaplastic Large Cell

  • Brain Cancer
  • Chemotherapy
  • Lymphoma
  • Oncology
  • Therapy

Ependymoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • February 2020
  • 132 pages

Lymphoma, or T-Cell Leukemia Gamma-Secretase Inhibitor RO## in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia GDCT## NCT##, CDR##; COG-ADVL##; U##CA##; NCI-2011-02024; ADVL## Oncology Acute Lymp

  • Brain Cancer
  • Cancer
  • Lymphoma
  • Oncology
  • Therapy
View report >

Medical Biotechnology Industry in the US - Forecast

  • September 2018
  • 60 pages

This is most likely because leukemias and lymphomas are characterized by a high mutational load.

  • Brain Cancer
  • Lymphoma
  • Medical Biotechnology
  • United States
  • Noxxon Pharma AG

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on